Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, Yoshino T, Saji S, Matsuda F. Kanai M, et al. Among authors: munemoto y. Cancer Med. 2023 Apr;12(7):7808-7814. doi: 10.1002/cam4.5541. Epub 2022 Dec 16. Cancer Med. 2023. PMID: 36524458 Free PMC article.
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Kono T, et al. Among authors: munemoto y. Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90. doi: 10.1007/s00280-013-2306-7. Cancer Chemother Pharmacol. 2013. PMID: 24121454 Free PMC article. Clinical Trial.
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S, Kono T. Matsuda C, et al. Among authors: munemoto y. Cancer Chemother Pharmacol. 2015 Jul;76(1):97-103. doi: 10.1007/s00280-015-2767-y. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983022 Free PMC article. Clinical Trial.
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Munemoto Y, et al. BMC Cancer. 2015 Oct 24;15:786. doi: 10.1186/s12885-015-1712-0. BMC Cancer. 2015. PMID: 26497654 Free PMC article. Clinical Trial.
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F. Kanai M, et al. Among authors: munemoto y. Ann Oncol. 2016 Jun;27(6):1143-1148. doi: 10.1093/annonc/mdw074. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27069012 Free article.
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Munemoto Y, Kanda M, Oba K, Kim HM, Takemoto H, Denda T, Nagata N, Takano N, Fukunaga M, Kataoka M, Tokunaga Y, Sakamoto J, Mishima H. Munemoto Y, et al. Cancer Chemother Pharmacol. 2018 May;81(5):829-838. doi: 10.1007/s00280-018-3556-1. Epub 2018 Mar 5. Cancer Chemother Pharmacol. 2018. PMID: 29508026 Clinical Trial.
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.
Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M. Kotaka M, et al. Among authors: munemoto y. ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018. ESMO Open. 2018. PMID: 29713499 Free PMC article.
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
Nishikawa K, Aoyama T, Oba MS, Yoshikawa T, Matsuda C, Munemoto Y, Takiguchi N, Tanabe K, Nagata N, Imano M, Oshiro M, Fukushima R, Kataoka M, Morita S, Tsuburaya A, Mishima H, Kono T, Sakamoto J. Nishikawa K, et al. Among authors: munemoto y. J Cancer. 2018 Apr 19;9(10):1725-1730. doi: 10.7150/jca.24733. eCollection 2018. J Cancer. 2018. PMID: 29805697 Free PMC article.
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer.
Kusumoto T, Ishiguro M, Nakatani E, Yoshida M, Inoue T, Nakamoto Y, Shiomi A, Takagane A, Sunami E, Shinozaki H, Takii Y, Maeda A, Ojima H, Hashida H, Mukaiya M, Yokoyama T, Nakamura M, Munemoto Y, Sugihara K. Kusumoto T, et al. Among authors: munemoto y. ESMO Open. 2018 Oct 7;3(6):e000428. doi: 10.1136/esmoopen-2018-000428. eCollection 2018. ESMO Open. 2018. PMID: 30425843 Free PMC article.
69 results